Question 1

Am I eligible for this trial based on my current treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

Question 2

How does inlexisertib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of this new combination treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests or procedures will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial fit into my overall cancer treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies clinical trial (NCT05957367). Contact the study team or your healthcare provider for specific answers.

What this study is about